Figure_2.tif (287.19 kB)
Prevalence of clinically relevant resistance to first line drugs (Stanford HIVdb) by antiretroviral class between 2007 and 2011.
figure
posted on 2014-03-17, 03:07 authored by Susana Monge, Vicente Guillot, Marta Alvarez, Natalia Chueca, Natalia Stella, Alejandro Peña, Rafael Delgado, Juan Córdoba, Antonio Aguilera, Carmen Vidal, Federico García, CoRISNRTI: nucleoside reverse transcriptase inhibitors (abacavir, emtricitabine, lamivudine and tenofovir); NNRTI: non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine); PI: protease inhibitors (atazanavir, darunavir and lopinavir). * p value for Chi-square test for trend.
History
Usage metrics
Categories
Keywords
biotechnologyApplied microbiologymicrobiologyMedical microbiologyMicrobial pathogensViral pathogensImmunodeficiency viruseshivMicrobial controlantimicrobialsantiviralsVirologyViral transmission and infectionClinical medicinehealth careHealth care policyScreening guidelinesTreatment guidelinesInfectious diseasesViral diseasesmathematicsApplied mathematicsalgorithmsresearch designClinical research designCohort studiesclinicallydrugsantiretroviral2007
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC